Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use

被引:205
|
作者
Baggish, Aaron L. [1 ,2 ]
Weiner, Rory B. [1 ,2 ]
Kanayama, Gen [3 ,4 ,5 ]
Hudson, James I. [3 ,4 ,5 ]
Lu, Michael T. [6 ,7 ]
Hoffmann, Udo [6 ,7 ]
Pope, Harrison G., Jr. [3 ,4 ,5 ]
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA
[4] McLean Hosp, Psychiat Epidemiol Res Program, 115 Mill St, Belmont, MA 02178 USA
[5] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[6] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA
关键词
anabolic-androgenic steroids; atherosclerosis; cardiology; cardiomyopathy; diastolic dysfunction; men; RISK-FACTORS; VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION; TISSUE DOPPLER; SOCIETY; WEIGHTLIFTERS; TESTOSTERONE; CONSEQUENCES; DYSFUNCTION; PREVALENCE;
D O I
10.1161/CIRCULATIONAHA.116.026945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting >= 2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean +/- SD left ventricular ejection fraction = 52 +/- 11% versus 63 +/- 8%; P < 0.001) and diastolic function (early relaxation velocity = 9.3 +/- 2.4 cm/second versus 11.1 +/- 2.0 cm/second; P < 0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49 +/- 10% versus 58 +/- 10%; P < 0.001) and diastolic function (early relaxation velocity = 8.9 +/- 2.4 cm/second versus 10.1 +/- 2.4 cm/second; P=0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3);P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
引用
收藏
页码:1991 / +
页数:26
相关论文
共 50 条
  • [31] Anabolic-Androgenic Steroid Use and Body Image in Men: A Growing Concern for Clinicians
    Kanayama, Gen
    Hudson, James I.
    Pope, Harrison G., Jr.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 89 (02) : 65 - 73
  • [32] Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective
    Corona, Giovanni
    Rastrelli, Giulia
    Marchiani, Sara
    Filippi, Sandra
    Morelli, Annamaria
    Sarchielli, Erica
    Sforza, Alessandra
    Vignozzi, Linda
    Maggi, Mario
    WORLD JOURNAL OF MENS HEALTH, 2022, 40 (02): : 165 - 178
  • [33] Misconceptions About Anabolic-Androgenic Steroid Abuse
    Kanayama, Gen
    Pope, Harrison G., Jr.
    PSYCHIATRIC ANNALS, 2012, 42 (10) : 371 - 375
  • [34] Impact of Health Authority Control Measures Aimed at Reducing the Illicit Use of Anabolic-Androgenic Steroids
    Vazquez-Mourelle, Raquel
    Carracedo-Martinez, Eduardo
    Figueiras, Adolfo
    EUROPEAN ADDICTION RESEARCH, 2018, 24 (01) : 28 - 36
  • [35] Associations of anabolic-androgenic steroid use with other behavioral disorders: an analysis using directed acyclic graphs
    Kanayama, Gen
    Pope, Harrison G., Jr.
    Hudson, James I.
    PSYCHOLOGICAL MEDICINE, 2018, 48 (15) : 2601 - 2608
  • [36] Long-Term Anabolic-Androgenic Steroid Use Is Associated With Left Ventricular Dysfunction
    Baggish, Aaron L.
    Weiner, Rory B.
    Kanayama, Gen
    Hudson, James I.
    Picard, Michael H.
    Hutter, Adolph M., Jr.
    Pope, Harrison G., Jr.
    CIRCULATION-HEART FAILURE, 2010, 3 (04) : 472 - U15
  • [37] Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes
    Fyksen, Tea Saetereng
    Vanberg, Paul
    Gjesdal, Knut
    von Lueder, Thomas G.
    Bjornerheim, Reidar
    Steine, Kjetil
    Atar, Dan
    Halvorsen, Sigrun
    SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, 2022, 32 (08) : 1170 - 1181
  • [38] Psychopathology among anabolic-androgenic steroid using and non-using female athletes in Norway
    Scarth, Morgan
    Jorstad, Marie Lindvik
    Reierstad, Amund
    Klonteig, Sandra
    Torgersen, Svenn
    Hullstein, Ingunn R.
    Bjornebekk, Astrid
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 155 : 295 - 301
  • [39] The Lifetime Prevalence of Anabolic-Androgenic Steroid Use and Dependence in Americans: Current Best Estimates
    Pope, Harrison G., Jr.
    Kanayama, Gen
    Athey, Alison
    Ryan, Erin
    Hudson, James I.
    Baggish, Aaron
    AMERICAN JOURNAL ON ADDICTIONS, 2014, 23 (04): : 371 - 377
  • [40] Review of oxymetholone:: A 17α-alkylated anabolic-androgenic steroid
    Pavlatos, AM
    Fultz, O
    Monberg, MJ
    Vootkur, A
    CLINICAL THERAPEUTICS, 2001, 23 (06) : 789 - 801